The leading diversified consumer health brand, pharmaceutical producer and medical device maker, all rolled into one simple investment is available at a fair quote in early June. Johnson & Johnson (JNJ) remains a solid buy against an overvalued stock market, perhaps its strongest setup since February. In return for your money, you get a higher dividend yield and lower than market P/E on forward results. High profit margins and extensive global sales to offset the coming devaluations in the U.S. Dollar are also noteworthy. Putting all the ideas together, the company may offer the best “risk-adjusted” investment argument in all of health care right now.

Johnson & Johnson's product line is extensive. Its consumer segment markets baby care products under the Johnson’s brand. The company also sells a variety of over-the-counter health related items under the names Listerine, Aveeno, Clean & Clear, Neutrogena, Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Pepcid, Stayfree, Carefree, o.b., Band-Aid, Neosporin and hundreds of others. The pharmaceutical segment offers various therapeutics, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic disease drugs. The medical device segment manufactures orthopedic, general surgery, biosurgical, endomechanical, energy, electrophysiology, sterilization, disinfection, diabetes, contact lens and cataract laser surgery items.

READ FULL ARTICLE HERE